Offering New Ways to Screen for Pancreatic Cancer in High-Risk Individuals
NCT02000089 · RecruitingThis study looks at different ways to screen for pancreatic cancer. It focuses on people who are at higher risk for this type of cancer. The goal is to find early signs of pancreatic cancer using special tests over a long period.
Locations and contact
This trial is running at 9 locations in the United States. All of them are currently recruiting.
United States9 locations · 9 recruiting
- Case Comprehensive Cancer Center, Case Western Medical ReserveCleveland, OhioRecruiting
- Columbia University Medical CenterNew York, New YorkRecruiting
- Dana Farber Cancer Center, Harvard UniversityBoston, MassachusettsRecruiting
- Johns Hopkins HospitalBaltimore, MarylandRecruiting
- NYU Langone Medical CenterNew York, New YorkRecruiting
- University of MichiganAnn Arbor, MichiganRecruiting
- University of PennsylvaniaPhiladelphia, PennsylvaniaRecruiting
- University of PittsburghPittsburgh, PennsylvaniaRecruiting
- Yale UniversityNew Haven, ConnecticutRecruiting
Who can join
Adults aged 18 and older can participate. People who have a strong family history of pancreatic cancer, certain gene mutations, or specific syndromes are welcome. Those with certain medical conditions, previous surgeries affecting the pancreas, or who are pregnant cannot join. The trial team will check who meets these guidelines.
What happens during the trial
Participants will be placed in groups based on their risk for pancreatic cancer. They will receive various tests, including special blood tests and imaging scans. Everyone will undergo procedures to collect pancreatic juice for testing. No one will be randomly assigned to groups; they will be placed based on their background and health history.
The trial team
Johns Hopkins University is leading this trial, supported by the National Cancer Institute, National Institutes of Health, and the American Association for Cancer Research. Dr. Michael Goggins is the main doctor in charge.
Important dates
The trial started on January 6, 2014, and is expected to finish around June 2029. It is currently enrolling new participants.
Additional information
The trial's ID number is NCT02000089. It is a Phase 3 trial, which means it is looking at how well the screening methods work and how safe they are. This trial is regulated by the FDA and aims to include about 9,000 people.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →